Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Oral COR588 in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Oral COR588 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LHP 588 (Primary)
  • Indications Periodontal disorders
  • Focus Adverse reactions; First in man
  • Sponsors Cortexyme

Most Recent Events

  • 20 Jul 2023 Results of subgroup analysis assessing efficacy in patients with Pg-positive saliva (Pg+), slowing cognitive decline compared with placebo presented at the Alzheimer's Association International Conference 2023
  • 24 May 2023 According to a Lighthouse Pharmaceuticals media release, study design of this trial and clinical efficacy data supporting will be presented at the ASCP annual meeting is being held May 30th - June 2nd, and the presentation will be on Tuesday May 30 in the Pharmaceuticals Pipeline session at 3:10 pm and a poster will also be presented on Wednesday May 31 at 11:15 am.
  • 19 Jul 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top